These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 17114012)
1. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. Liau SS; Ashley SW; Whang EE J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012 [TBL] [Abstract][Full Text] [Related]
2. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells. Cao YD; Huang PL; Sun XC; Ma J; Jin ZL; Cheng HY; Xu RZ; Li F; Qin SK; Deng YX; Ge XL Chin Med J (Engl); 2011 Apr; 124(7):1061-8. PubMed ID: 21542969 [TBL] [Abstract][Full Text] [Related]
3. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Liau SS; Whang E Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Liau SS; Jazag A; Ito K; Whang EE Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093 [TBL] [Abstract][Full Text] [Related]
5. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Yao J; Qian C Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106 [TBL] [Abstract][Full Text] [Related]
8. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. Jiang C; Yi XP; Shen H; Li YX World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919 [TBL] [Abstract][Full Text] [Related]
9. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE J Am Coll Surg; 2004 Jun; 198(6):953-9. PubMed ID: 15194078 [TBL] [Abstract][Full Text] [Related]
10. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Liau SS; Rocha F; Matros E; Redston M; Whang E Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350 [TBL] [Abstract][Full Text] [Related]
11. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
12. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261 [TBL] [Abstract][Full Text] [Related]
14. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439 [TBL] [Abstract][Full Text] [Related]
15. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231 [TBL] [Abstract][Full Text] [Related]
16. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
17. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287 [TBL] [Abstract][Full Text] [Related]
18. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine resistance in pancreatic cancer: picking the key players. Kim MP; Gallick GE Clin Cancer Res; 2008 Mar; 14(5):1284-5. PubMed ID: 18316544 [No Abstract] [Full Text] [Related]
20. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE Cancer Res; 2004 Jun; 64(11):3987-93. PubMed ID: 15173012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]